Immune cells drive inflammatory bone marrow shift with age

Bone marrow is the production site for all blood cells. Normally, it generates a balanced mix of red blood cells, immune cells, and platelets. With aging, that balance shifts toward more myeloid cells (inflammation-related immune cells) and fewer lymphocytes. This phenomenon, called myeloid bias, contributes to inflammaging, the chronic low-grade inflammation linked to age-related diseases.

Researchers report in Nature Aging that a specific type of T cell, the cytotoxic CD4+ T cell, actively promotes this shift. The researchers showed that these cells stimulate myeloid cell production in the bone marrow through the CCL5-CCR5 axis. CCL5 is a chemokine (a chemical attractant signal) that acts via the receptor CCR5.

An existing drug as a candidate

Notably, the researchers not only mapped the mechanism but also tested a clinically approved drug: maraviroc. This drug blocks CCR5 and is already used in HIV treatment. In aged mice, maraviroc partially restored immune balance, reducing myeloid bias. The findings are preliminary and limited to animal models, but the drug’s clinical availability makes it an interesting candidate for follow-up research in humans.

For longevity research, this is a meaningful finding. Myeloid bias and inflammaging have long been recognized features of aging, but the specific cell type driving the process was unclear. With cytotoxic CD4+ T cells identified as a key driver, a more concrete intervention target emerges.

What does this mean in the longer term?

The key question is whether maraviroc or similar CCR5 blockers can achieve the same immune rebalancing in humans. Clinical trials are needed. There are also potential risks: CCR5 also plays a role in infection defense, so full blockade is not without concern. Still, the direction is promising: a well-studied existing drug that appears to address an age-related immune problem.

Read the original article